Spinoff secures $5-million USD to decode antibodies for potential treatments for COVID-19 and other illnesses

Tuesday, July 28, 2020

A world-leading University of Waterloo spinoff company, that decodes blood samples for potential treatments for illnesses like cancer and COVID-19, is expanding operations with the help of a $5-million USD investment.

Bin Ma, a University of Waterloo computer science professor who cofounded Rapid Novor in 2015, says the company’s technology is the most advanced in the world when it comes to deciphering the complex workings of antibody proteins, a process called sequencing.

Learn more about the work of Ma and Rapid Novor.